40 results
P
running group
I/C
running, control group
O
cartilage volume, cartilage thickness, T2, COMP (immediately or 0.5 h after running)
P
Standardbred and Thoroughbred horses
I/C
acute sodium bicarbonate administration, control group
O
running performance
P
soccer players
I/C
small-sided games (SSGs)-based interventions, running-based high-intensity interval training (HIIT) interventions
O
repeated sprint ability (RSA)
P
lung disease, li, ipf
I/C
baicalin, no intervention
O
reduced inflammation, decreased apoptosis, protected against progression
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
nurses
I/C
health education and counselling, case management and health promotion, running specialist clinics, no intervention
O
increased hepatitis B screening and detection rates, increased odds of hepatitis B virus vaccination, improved immunity rate, enhanced patient adherence to antiviral treatment and monitoring of liver comorbidities
P
approximately 1911 individuals
I/C
gathered from 8 laboratories which run population studies with the comet-based in vitro DNA repair assay, correlated with various host factors
O
BER incision activity data were normalized and subsequently correlated with various host factors. BER was found to be significantly higher in women. Although it is generally accepted that age is inversely related to DNA repair, no overall effect of age was found, but sex differences were most pronounced in the oldest quartile (>61 years). No effect of smoking or occupational exposures was found. A body mass index (BMI) above 25 kg/m
P
individuals
I/C
mobile application-based interventions, no intervention, traditional interventions
O
physical activity (PA), self-efficacy, sedentarism
P
women with hot flashes
I/C
active treatment type (hormone therapy /non- hormone therapy /complementary and alternative medicine), administration route (oral/non-oral), study region (in/excluded the US), breast cancer population (in/excluded), entry criteria of hot flash severity (moderate to severe only/all included), parallel or crossover study, placebo run-in period before treatment (yes/no), menopausal status (postmenopausal only/include perimenopausal/include premenopausal), placebo response
O
reduction in the mean number of hot flash frequency from baseline